OBJECTIVE: Treatment with the anti-CD20 monoclonal antibody (mAb) rituximab is effective in rheumatoid arthritis (RA). Marked depletion of circulating B cells, seen in almost all patients, does not correlate with efficacy. The potential synovial immunomodulatory effects of rituximab have not been fully defined. METHODS: The ARISE trial is an open label, serial synovial biopsy (pre-treatment and 8 weeks) study of rituximab, given 1 g intravenously on days 0 and 14 without peri-infusional steroids, in active RA patients on concomitant methotrexate (MTX). Synovial tissue was analysed by immunohistochemistry with digital image analysis and gene expression by real-time PCR. RESULTS: The mean (SD) baseline DAS28 score was 6.5 (0.4), and mean MTX dose 17.3 mg/week. Of 13 patients, 11 had failed prior tumour necrosis factor (TNF) inhibitor therapy. With treatment, all patients experienced near complete depletion of circulating B cell numbers. During the 6 months after treatment, 7/13 patients achieved an American College of Rheumatology (ACR) 20% improvement (ACR20) response, 3/13 an ACR50 response and 2/13 an ACR70 response. There was a significant decrease in synovial B cells after treatment, but only a small trend towards greater reduction among clinical responders. Among the three patients with ACR50 responses there was a significant decrease in synovial immunoglobulin synthesis. CONCLUSIONS: These data suggest that unlike those in circulation, synovial B cells are decreased but are not eliminated by rituximab therapy. Patients with higher levels of response may have more consistent depletion of synovial B cells, and may also have an alteration in synovial B cell function, as indicated by decreases in synovial immunoglobulin synthesis. Thus, effects on synovial B cells may be necessary but not sufficient for inducing clinical efficacy. Other effects, such as on primary lymph organ B cell antigen presentation or cytokine production, may be operative.
OBJECTIVE: Treatment with the anti-CD20 monoclonal antibody (mAb) rituximab is effective in rheumatoid arthritis (RA). Marked depletion of circulating B cells, seen in almost all patients, does not correlate with efficacy. The potential synovial immunomodulatory effects of rituximab have not been fully defined. METHODS: The ARISE trial is an open label, serial synovial biopsy (pre-treatment and 8 weeks) study of rituximab, given 1 g intravenously on days 0 and 14 without peri-infusional steroids, in active RApatients on concomitant methotrexate (MTX). Synovial tissue was analysed by immunohistochemistry with digital image analysis and gene expression by real-time PCR. RESULTS: The mean (SD) baseline DAS28 score was 6.5 (0.4), and mean MTX dose 17.3 mg/week. Of 13 patients, 11 had failed prior tumour necrosis factor (TNF) inhibitor therapy. With treatment, all patients experienced near complete depletion of circulating B cell numbers. During the 6 months after treatment, 7/13 patients achieved an American College of Rheumatology (ACR) 20% improvement (ACR20) response, 3/13 an ACR50 response and 2/13 an ACR70 response. There was a significant decrease in synovial B cells after treatment, but only a small trend towards greater reduction among clinical responders. Among the three patients with ACR50 responses there was a significant decrease in synovial immunoglobulin synthesis. CONCLUSIONS: These data suggest that unlike those in circulation, synovial B cells are decreased but are not eliminated by rituximab therapy. Patients with higher levels of response may have more consistent depletion of synovial B cells, and may also have an alteration in synovial B cell function, as indicated by decreases in synovial immunoglobulin synthesis. Thus, effects on synovial B cells may be necessary but not sufficient for inducing clinical efficacy. Other effects, such as on primary lymph organ B cell antigen presentation or cytokine production, may be operative.
Authors: Paul Emery; Roy Fleischmann; Anna Filipowicz-Sosnowska; Joy Schechtman; Leszek Szczepanski; Arthur Kavanaugh; Artur J Racewicz; Ronald F van Vollenhoven; Nicole F Li; Sunil Agarwal; Eva W Hessey; Timothy M Shaw Journal: Arthritis Rheum Date: 2006-05
Authors: Geraldine Cambridge; William Stohl; Maria J Leandro; Thi-Sau Migone; David M Hilbert; Jonathan C W Edwards Journal: Arthritis Rheum Date: 2006-03
Authors: Jonathan C W Edwards; Leszek Szczepanski; Jacek Szechinski; Anna Filipowicz-Sosnowska; Paul Emery; David R Close; Randall M Stevens; Tim Shaw Journal: N Engl J Med Date: 2004-06-17 Impact factor: 91.245
Authors: David L Boyle; Sanna Rosengren; William Bugbee; Arthur Kavanaugh; Gary S Firestein Journal: Arthritis Res Ther Date: 2003-10-08 Impact factor: 5.156
Authors: Eliana A G Reis; Daniel A Athanazio; Isabella Lima; Natália Oliveira e Silva; Jorge Clarencio S Andrade; Ronden N Jesus; Lúcio M Barbosa; Mitermayer G Reis; Mittermayer B Santiago Journal: Rheumatol Int Date: 2008-09-28 Impact factor: 2.631
Authors: Magda Nakou; Georgios Katsikas; Prodromos Sidiropoulos; George Bertsias; Eva Papadimitraki; Amalia Raptopoulou; Helen Koutala; Helen A Papadaki; Herakles Kritikos; Dimitrios T Boumpas Journal: Arthritis Res Ther Date: 2009-08-28 Impact factor: 5.156
Authors: Maria Rehnberg; Sylvie Amu; Andrej Tarkowski; Maria I Bokarewa; Mikael Brisslert Journal: Arthritis Res Ther Date: 2009-08-17 Impact factor: 5.156
Authors: Erik af Klint; Anca I Catrina; Peter Matt; Petra Neregråd; Jon Lampa; Ann-Kristin Ulfgren; Lars Klareskog; Staffan Lindblad Journal: Arthritis Res Ther Date: 2009-06-02 Impact factor: 5.156
Authors: Burkhard Möller; Daniel Aeberli; Stefan Eggli; Martin Fuhrer; Istvan Vajtai; Esther Vögelin; Hans-Rudolf Ziswiler; Clemens A Dahinden; Peter M Villiger Journal: Arthritis Res Ther Date: 2009-05-06 Impact factor: 5.156